In CTCL, a sequence mutation in pro-IL-16 reduces p27KIP1 levels, enhancing cell proliferation; in MM, overexpression of secreted IL-16 induces plasma cell proliferation; and in breast cancer, increased IL-16 recruits CD4+ pro-tumor macrophages [32]. This evidence concerns the gene IL16 and breast cancer.